Thrombin inhibitor and preparation and use thereof
AssigneeBoehringer Mannheim GmbH
InventorsHans Port, Jurgen Schrenk, Peter Wunderwald
Life of this patent
Estimating the term…
Abstract
Thrombin inhibitor comprising a glycoprotein of a molecular weight of 68,000 to 69,000 Dalton and an isoelectric point of pH 4.5, and is further characterized in that it inhibits thrombin in the presence of dextran sulfate at least twice as strongly as in the presence of heparin, differs immunologically from antithrombin III, and does not inhibit factor Xa, plasmin and trypsin.
Claims6
Thrombin inhibitor comprising a glycoprotein of a molecular weight of 68,000 to 69,000 Dalton and an isoelectric point of pH 4.5, obtained by the process of treating plasma, serum or a fraction obtained therefrom with an insoluble carrier-bound heparin or dextran sulfate, eluting the latter, after removal of non-bound material, with a salt solution having an ion strength of 0.12 to 0.36 and a pH value from 6.5 to 8.3, and recovering the thrombin inhibitor from the eluate, and is further characterized in that it inhibits thrombin in the presence of heparin, differs immunologically from antithrombin III, and does not inhibit factor Xa, plasmin and trypsin.
Process for obtaining a thrombin inhibitor comprising a glycoprotein of a molecular weight of 68,000 to 69,000 Dalton and an isoelectric point of pH 4.5, and characterized in that it inhibits thrombin in the presence of dextran sulfate at least twice as strongly as in the presence of heparin, differs immunologically from antithrombin III, and does not inhibit factor Xa, plasmin and trypsin which process comprises the steps of
- treating plasma, serum or a fraction obtained therefrom with an insoluble carrier-bound heparin or dextran sulfate, eluting the latter, after removal of non-bound material, with a salt solution having an ion strength of 0.12 to 0.36 and a pH value from 6.5 to 8.3, and recovering the thrombin inhibitor from the eluate.
Dependencies are inferred from the claim text.